---
document_datetime: 2025-12-02 05:04:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-viatris.html
document_name: rivaroxaban-viatris.html
version: success
processing_time: 0.1289861
conversion_datetime: 2025-12-29 22:45:29.446382
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rivaroxaban Viatris (previously Rivaroxaban Mylan)

[RSS](/en/individual-human-medicine.xml/67490)

##### Authorised

This medicine is authorised for use in the European Union

rivaroxaban Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rivaroxaban Viatris (previously Rivaroxaban Mylan)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76953)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rivaroxaban Mylan is an anticoagulant medicine (a medicine that prevents blood clotting) used:

- to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from re-occurring in adults;
- to prevent venous thromboembolism (VTE, the formation of blood clots in the veins) in adults who are undergoing surgery to replace a hip or knee;
- to treat VTE and prevent VTE from re-occurring in children and adolescents aged less than 18 years weighing more than 30 kg;
- to prevent stroke (caused by a clot in a blood vessel in the brain) and systemic embolism (a clot in other blood vessels) in adults with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart);
- to prevent atherothrombotic events (such as heart attack, stroke or death from heart disease) in adults:
    - after an acute coronary syndrome, when it is used with an antiplatelet medicine (which prevents the formation of blood clots). Acute coronary syndrome consists of conditions such as unstable angina (a severe type of chest pain) and heart attack;
    - at high risk of ischaemic events (problems caused by restricted blood supply) who have coronary artery disease (disease caused by obstructed blood supply to the heart muscle) or peripheral artery disease (disease caused by defective blood flow in the arteries). It is used with aspirin.

Rivaroxaban Mylan contains the active substance rivaroxaban and is a 'generic medicine'. This means that Rivaroxaban Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Xarelto. For more information on generic medicines, see the question-and-answer document [here](/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Rivaroxaban Mylan used?

Rivaroxaban Mylan is available as tablets of various strengths. The dose and duration of treatment with Rivaroxaban Mylan depend on what it is being used for and the patient's risk of bleeding. For children, the form, dose and duration of treatment also depend on the patient's age and weight. Rivaroxaban Mylan is given at a lower dose when used in combination with an antiplatelet medicine such as aspirin, clopidogrel or ticlopidine. The doctor will regularly evaluate the benefits of ongoing treatment against the risk of excessive or internal bleeding.

The medicine can only be obtained with a prescription. For more information about using Rivaroxaban Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Rivaroxaban Mylan work?

The active substance in Rivaroxaban Mylan, rivaroxaban, is a 'factor Xa inhibitor'. This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin. Thrombin is central to the process of blood clotting. By blocking factor Xa, the levels of thrombin decrease, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.

## How has Rivaroxaban Mylan been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Xarelto, and do not need to be repeated for Rivaroxaban Mylan.

As for every medicine, the company provided data on the quality of Rivaroxaban Mylan. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Rivaroxaban Mylan?

Because Rivaroxaban Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Rivaroxaban Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Rivaroxaban Mylan has been shown to have comparable quality and to be bioequivalent to Xarelto. Therefore, the Agency's view was that, as for Xarelto, the benefits of Rivaroxaban Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rivaroxaban Mylan?

The company that markets Rivaroxaban Mylan will provide an educational pack for doctors who prescribe Rivaroxaban Mylan, containing important safety information including on the risk of bleeding during treatment with Rivaroxaban Mylan and how to manage this risk. In addition, prescribers will receive a patient alert card to give to patients receiving Rivaroxaban Mylan containing key safety reminders for patients.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rivaroxaban Mylan have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rivaroxaban Mylan are continuously monitored. Suspected side effects reported with Rivaroxaban Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rivaroxaban Mylan

Rivaroxaban Mylan received a marketing authorisation valid throughout the EU on 12 November 2021.

Rivaroxaban Mylan : EPAR - Medicine overview

Reference Number: EMA/534175/2021

English (EN) (167.78 KB - PDF)

**First published:** 29/11/2021

[View](/en/documents/overview/rivaroxaban-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-813)

български (BG) (182.34 KB - PDF)

**First published:**

29/11/2021

[View](/bg/documents/overview/rivaroxaban-mylan-epar-medicine-overview_bg.pdf)

español (ES) (159.92 KB - PDF)

**First published:**

29/11/2021

[View](/es/documents/overview/rivaroxaban-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (180.43 KB - PDF)

**First published:**

29/11/2021

[View](/cs/documents/overview/rivaroxaban-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (157.86 KB - PDF)

**First published:**

29/11/2021

[View](/da/documents/overview/rivaroxaban-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (162.9 KB - PDF)

**First published:**

29/11/2021

[View](/de/documents/overview/rivaroxaban-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (146.75 KB - PDF)

**First published:**

29/11/2021

[View](/et/documents/overview/rivaroxaban-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (182.01 KB - PDF)

**First published:**

29/11/2021

[View](/el/documents/overview/rivaroxaban-mylan-epar-medicine-overview_el.pdf)

français (FR) (160.24 KB - PDF)

**First published:**

29/11/2021

[View](/fr/documents/overview/rivaroxaban-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (179.61 KB - PDF)

**First published:**

29/11/2021

[View](/hr/documents/overview/rivaroxaban-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (158.26 KB - PDF)

**First published:**

29/11/2021

[View](/it/documents/overview/rivaroxaban-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (197.4 KB - PDF)

**First published:**

29/11/2021

[View](/lv/documents/overview/rivaroxaban-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (180.99 KB - PDF)

**First published:**

29/11/2021

[View](/lt/documents/overview/rivaroxaban-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (181.04 KB - PDF)

**First published:**

29/11/2021

[View](/hu/documents/overview/rivaroxaban-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (182.56 KB - PDF)

**First published:**

29/11/2021

[View](/mt/documents/overview/rivaroxaban-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (158.95 KB - PDF)

**First published:**

29/11/2021

[View](/nl/documents/overview/rivaroxaban-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (183.26 KB - PDF)

**First published:**

29/11/2021

[View](/pl/documents/overview/rivaroxaban-mylan-epar-medicine-overview_pl.pdf)

português (PT) (159.17 KB - PDF)

**First published:**

29/11/2021

[View](/pt/documents/overview/rivaroxaban-mylan-epar-medicine-overview_pt.pdf)

română (RO) (180.02 KB - PDF)

**First published:**

29/11/2021

[View](/ro/documents/overview/rivaroxaban-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (179.94 KB - PDF)

**First published:**

29/11/2021

[View](/sk/documents/overview/rivaroxaban-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (179.18 KB - PDF)

**First published:**

29/11/2021

[View](/sl/documents/overview/rivaroxaban-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (156.23 KB - PDF)

**First published:**

29/11/2021

[View](/fi/documents/overview/rivaroxaban-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (157.3 KB - PDF)

**First published:**

29/11/2021

[View](/sv/documents/overview/rivaroxaban-mylan-epar-medicine-overview_sv.pdf)

Rivaroxaban Viatris : EPAR - Risk management plan

English (EN) (565.57 KB - PDF)

**First published:** 29/11/2021

**Last updated:** 23/07/2025

[View](/en/documents/rmp/rivaroxaban-viatris-epar-risk-management-plan_en.pdf)

## Product information

Rivaroxaban Viatris : EPAR - Product information

English (EN) (1.41 MB - PDF)

**First published:** 29/11/2021

**Last updated:** 05/11/2025

[View](/en/documents/product-information/rivaroxaban-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-755)

български (BG) (2.23 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/rivaroxaban-viatris-epar-product-information_bg.pdf)

español (ES) (2.13 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/es/documents/product-information/rivaroxaban-viatris-epar-product-information_es.pdf)

čeština (CS) (1.93 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/rivaroxaban-viatris-epar-product-information_cs.pdf)

dansk (DA) (1.86 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/da/documents/product-information/rivaroxaban-viatris-epar-product-information_da.pdf)

Deutsch (DE) (1.64 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/de/documents/product-information/rivaroxaban-viatris-epar-product-information_de.pdf)

eesti keel (ET) (1.72 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/et/documents/product-information/rivaroxaban-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (1.9 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/el/documents/product-information/rivaroxaban-viatris-epar-product-information_el.pdf)

français (FR) (920.48 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/rivaroxaban-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (1.99 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/rivaroxaban-viatris-epar-product-information_hr.pdf)

íslenska (IS) (1.95 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/is/documents/product-information/rivaroxaban-viatris-epar-product-information_is.pdf)

italiano (IT) (1.8 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/it/documents/product-information/rivaroxaban-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (1.51 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/rivaroxaban-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.05 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/rivaroxaban-viatris-epar-product-information_lt.pdf)

magyar (HU) (2.19 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/rivaroxaban-viatris-epar-product-information_hu.pdf)

Malti (MT) (2.33 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/rivaroxaban-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (1.99 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/rivaroxaban-viatris-epar-product-information_nl.pdf)

norsk (NO) (1.43 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/no/documents/product-information/rivaroxaban-viatris-epar-product-information_no.pdf)

polski (PL) (2.19 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/rivaroxaban-viatris-epar-product-information_pl.pdf)

português (PT) (1.4 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/rivaroxaban-viatris-epar-product-information_pt.pdf)

română (RO) (2.65 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/rivaroxaban-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (2.21 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/rivaroxaban-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (2.22 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/rivaroxaban-viatris-epar-product-information_sl.pdf)

Suomi (FI) (1.92 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/rivaroxaban-viatris-epar-product-information_fi.pdf)

svenska (SV) (1.78 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/rivaroxaban-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000297251 05/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rivaroxaban Viatris : EPAR - All authorised presentations

English (EN) (84.56 KB - PDF)

**First published:** 29/11/2021

**Last updated:** 05/11/2025

[View](/en/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-949)

български (BG) (123.85 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/bg/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (94.52 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/es/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (92.86 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/cs/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (79.15 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/da/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (90.3 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/de/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (1.71 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/et/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (149.37 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/el/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (75.23 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/fr/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (129.89 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/hr/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (77.48 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/is/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (58.49 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/it/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (103.62 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/lv/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (133.56 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/lt/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (132.29 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/hu/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (80.56 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/mt/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (90.56 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/nl/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (94.98 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/no/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.13 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/pl/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (89.74 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/pt/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (119.06 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/ro/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (114.3 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sk/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (116.28 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sl/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (101.07 KB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/fi/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (1.77 MB - PDF)

**First published:**

29/11/2021

**Last updated:**

05/11/2025

[View](/sv/documents/all-authorised-presentations/rivaroxaban-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rivaroxaban Viatris (previously Rivaroxaban Mylan) Active substance rivaroxaban International non-proprietary name (INN) or common name rivaroxaban Therapeutic area (MeSH)

- Venous Thromboembolism
- Pulmonary Embolism
- Acute Coronary Syndrome
- Stroke
- Coronary Artery Disease
- Peripheral Arterial Disease
- Atrial Fibrillation

Anatomical therapeutic chemical (ATC) code B01AF01

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.

Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

------

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

-------

**Adults**

**Paediatric population**

**Paediatric population** Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

## Authorisation details

EMA product number EMEA/H/C/005600

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 16/09/2021 Marketing authorisation issued 12/11/2021 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rivaroxaban Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.59 KB - PDF)

**First published:** 04/06/2025

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/rivaroxaban-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rivaroxaban Viatris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (161.55 KB - PDF)

**First published:** 06/03/2023

**Last updated:** 04/06/2025

[View](/en/documents/procedural-steps-after/rivaroxaban-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Rivaroxaban Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/560715/2021

English (EN) (602.71 KB - PDF)

**First published:** 29/11/2021

[View](/en/documents/assessment-report/rivaroxaban-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rivaroxaban Mylan

Adopted

Reference Number: EMA/CHMP/513776/2021

English (EN) (153.07 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rivaroxaban-mylan_en.pdf)

#### News on Rivaroxaban Viatris (previously Rivaroxaban Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Rivaroxaban Viatris : EPAR - Product information - tracked changes

English (EN) (595.1 KB - DOCX)

**First published:** 04/06/2025

[View](/en/documents/product-information-tracked-changes/rivaroxaban-viatris-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-169)

български (BG) (871.4 KB - DOCX)

**First published:**

04/06/2025

[View](/bg/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.01 MB - DOCX)

**First published:**

04/06/2025

[View](/es/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (859.22 KB - DOCX)

**First published:**

04/06/2025

[View](/cs/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (726.26 KB - DOCX)

**First published:**

04/06/2025

[View](/da/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (641.06 KB - DOCX)

**First published:**

04/06/2025

[View](/de/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (674.59 KB - DOCX)

**First published:**

04/06/2025

[View](/et/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (847.75 KB - DOCX)

**First published:**

04/06/2025

[View](/el/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (620.91 KB - DOCX)

**First published:**

04/06/2025

[View](/fr/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (595.25 KB - DOCX)

**First published:**

04/06/2025

[View](/hr/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (813.47 KB - DOCX)

**First published:**

04/06/2025

[View](/is/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_is.docx)

italiano (IT) (764.41 KB - DOCX)

**First published:**

04/06/2025

[View](/it/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (738.44 KB - DOCX)

**First published:**

04/06/2025

[View](/lv/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (541.64 KB - DOCX)

**First published:**

04/06/2025

[View](/lt/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (719.73 KB - DOCX)

**First published:**

04/06/2025

[View](/hu/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (739.8 KB - DOCX)

**First published:**

04/06/2025

[View](/mt/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (618.36 KB - DOCX)

**First published:**

04/06/2025

[View](/nl/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.21 MB - DOCX)

**First published:**

04/06/2025

[View](/no/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_no.docx)

polski (PL) (807.55 KB - DOCX)

**First published:**

04/06/2025

[View](/pl/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_pl.docx)

português (PT) (711.44 KB - DOCX)

**First published:**

04/06/2025

[View](/pt/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (681.08 KB - DOCX)

**First published:**

04/06/2025

[View](/ro/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (946.48 KB - DOCX)

**First published:**

04/06/2025

[View](/sk/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (748.06 KB - DOCX)

**First published:**

04/06/2025

[View](/sl/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (756.91 KB - DOCX)

**First published:**

04/06/2025

[View](/fi/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (560.41 KB - DOCX)

**First published:**

04/06/2025

[View](/sv/documents/product-information-tracked-changes/rivaroxaban-mylan-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)